Heparins

Qilian International Holding Group Limited Enters into Investment Agreement for Pig By-product Processing Project in Chongqing

Retrieved on: 
Friday, July 9, 2021
Western China, Administrative divisions of China, Geography of China, Glycosaminoglycans, Heparins, Geography of Asia, Chongqing, Gansu, Qilian Mountains, Pork

The Project is expected to receive preferential policies from the government at the national, municipal and local levels.

Key Points: 
  • The Project is expected to receive preferential policies from the government at the national, municipal and local levels.
  • Mr. Zhanchang Xin, Chairman and CEO of the Company, commented, We are very pleased to work with CJT on the Project.
  • As a key area for pig breeding and pork production in China, Chongqing has sufficient raw materials for the production of heparin sodium preparations.
  • Qilian International Holding Group Limited, headquartered in Gansu, China, is a pharmaceutical and chemical products manufacturer in China.

Perosphere Technologies Announces CE-IVD Marking of the Perosphere Technologies PoC Coagulometer System for DOAC and Heparin Testing

Retrieved on: 
Friday, May 7, 2021
Chemical compounds, Clinical medicine, Branches of biology, Heparins, Blood tests, Anticoagulant, Coagulation system, Hematology, Coagulation, Apixaban, Low-molecular-weight heparin, Thrombus

The PoC Coagulometer technology measures the intrinsic clotting time of fresh whole blood, providing an unprecedented look at blood coagulability, addressing several unmet medical needs.

Key Points: 
  • The PoC Coagulometer technology measures the intrinsic clotting time of fresh whole blood, providing an unprecedented look at blood coagulability, addressing several unmet medical needs.
  • In particular, the PoC Coagulometer is the first point of care device to enter the market specifically designed for direct oral anticoagulant (DOAC, e.g., rivaroxaban, apixaban, and edoxaban) and low molecular weight heparin (LWMH) coagulation testing in both emergency and outpatient settings.
  • "We believe our PoC Coagulometer system will change the paradigm for managing DOAC and heparin therapy in emergency settings and beyond.
  • "\nPerosphere Technologies plans to launch the PoC Coagulometer system in select EU countries later this year, with an expanded launch planned for early Q1 2022.

Valeo Pharma's anti-blood clotting medication is now covered by public insurance in Ontario - proving fast-track to market model

Retrieved on: 
Thursday, April 29, 2021
Hematology, Health sciences, Health care, Health, Heparins, Pharmaceuticals policy, Drugs, Low-molecular-weight heparin, Biosimilar, Generic drug, Venous thrombosis, Thrombosis

b'VANCOUVER, BC, April 29, 2021 /PRNewswire/ - Valeo Pharma (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) has reached an agreement with the Ontario Public Drug Program to cover the costs of Redesca and Redesca HP anticoagulants that reduce the risks of blood clots.\nLaunched as a public entity in 2019 Valeo is a specialty pharma company that commercialises prescription products in Canada with a focus on Neurodegenerative Diseases, Oncology and Hospital Specialty Products.\nValeo\'s business model side-steps the typical pharma-development pipeline of animal-trials, human-trials and applications for regulatory approval.\nVPH partners with pharma companies that have drugs already approved in other jurisdictions, providing those companies with the infrastructure and expertise to navigate the Canadian landscape of drug commercialization.\nThe Product Listing Agreement (PLA) with the Executive Officer of the Ontario Public Drug Program means that eligible Ontario patients requiring Redesca and Redesca HP are insured for the costs of the drugs.\nRedesca is a low molecular weight heparin (LMWH) biosimilar.\nLMWHs are injectable anticoagulant drugs used primarily to treat and prevent deep vein thrombosis and pulmonary embolism.\nDeep vein thrombosis (DVT): a blood clot that forms in a deep vein, most commonly the leg or pelvis.\nPulmonary embolism (PE): a blood clot that becomes dislodged and passes through blood vessels before reaching the lungs.\n"Biosimilar drugs are often confused with generic drugs," explains The Cancer Center , "Both are marketed as cheaper versions of costly name-brand drugs.

Key Points: 
  • b'VANCOUVER, BC, April 29, 2021 /PRNewswire/ - Valeo Pharma (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) has reached an agreement with the Ontario Public Drug Program to cover the costs of Redesca and Redesca HP anticoagulants that reduce the risks of blood clots.\nLaunched as a public entity in 2019 Valeo is a specialty pharma company that commercialises prescription products in Canada with a focus on Neurodegenerative Diseases, Oncology and Hospital Specialty Products.\nValeo\'s business model side-steps the typical pharma-development pipeline of animal-trials, human-trials and applications for regulatory approval.\nVPH partners with pharma companies that have drugs already approved in other jurisdictions, providing those companies with the infrastructure and expertise to navigate the Canadian landscape of drug commercialization.\nThe Product Listing Agreement (PLA) with the Executive Officer of the Ontario Public Drug Program means that eligible Ontario patients requiring Redesca and Redesca HP are insured for the costs of the drugs.\nRedesca is a low molecular weight heparin (LMWH) biosimilar.\nLMWHs are injectable anticoagulant drugs used primarily to treat and prevent deep vein thrombosis and pulmonary embolism.\nDeep vein thrombosis (DVT): a blood clot that forms in a deep vein, most commonly the leg or pelvis.\nPulmonary embolism (PE): a blood clot that becomes dislodged and passes through blood vessels before reaching the lungs.\n"Biosimilar drugs are often confused with generic drugs," explains The Cancer Center , "Both are marketed as cheaper versions of costly name-brand drugs.
  • Generic drugs are identical to the original in chemical composition, biosimilar drugs are " highly similar ," but close enough to accomplish the same therapeutic and clinical result".\nBlood clots are a leading cause of preventable hospital death in the United States.\nRedesca has already clocked more than 150 million patient days in foreign markets.\n"The regulatory approval of Redesca is a significant corporate milestone for Valeo and good news for the Canadian healthcare system," stated Valeo CEO Steve Saviuk, "Mandatory use of biosimilars is expected to deliver significant savings to provincial healthcare plans.
  • "\nOn April 27, 2021 VPH announced that it upsized and closed a $6.645 million non-brokered private placement of unsecured non-convertible debenture units.\nThe Debentures will mature at the latest 9 months after the closing and bear interest at a rate of 8% per annum from the date of issue, payable in cash, semi-annually in arrears.\n"I cannot over emphasize what a pivotal year 2021 is becoming with the recent launch of Redesca and the imminent launches of Enerzair Breezhaler and Atectura Breezhaler," added Saviuk.\n"With Ontario representing 37% of the Canadian market for LMWHs, the listing of Redesca on the Ontario public formulary is a key milestone for the Redesca commercialization program," stated Frederic Fasano, President and COO of Valeo.\n"This is welcome news for millions of Canadians who rely on public insurance to access their prescription medications," added Fasano, "and for the Government of Ontario who will benefit from significant savings resulting from the listing of the first LMWH biosimilar".\nVPH anticipates that public insurance coverage for Redesca in other provinces will follow.\n'

Valeo Pharma's Redesca® and Redesca HP® to Be Covered Under the Ontario Public Drug Benefit Program

Retrieved on: 
Wednesday, April 28, 2021
Heparins, Hematology, Clinical medicine, Medical specialties, Medicine, Low-molecular-weight heparin, Venous thrombosis, Anticoagulant, Pulmonary embolism, Biosimilar, Thrombosis, Deep vein thrombosis

(CSE: VPH)(OTCQB: VPHIF)(FSE: VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, today announced that it has entered into a Product Listing Agreement ("PLA") with the Executive Officer of the Ontario Public Drug Program for the listing ofRedescaand Redesca HP, its low molecular weight heparin ("LMWH") biosimilar, on the Ontario Drug Benefit Formulary effective April 30, 2021.\n"With Ontario representing 37% of the Canadian market for LMWHs, the listing of Redesca on the Ontario public formulary is a key milestone for the Redesca commercialization program", said Frederic Fasano, President and COO of Valeo.

Key Points: 
  • (CSE: VPH)(OTCQB: VPHIF)(FSE: VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, today announced that it has entered into a Product Listing Agreement ("PLA") with the Executive Officer of the Ontario Public Drug Program for the listing ofRedescaand Redesca HP, its low molecular weight heparin ("LMWH") biosimilar, on the Ontario Drug Benefit Formulary effective April 30, 2021.\n"With Ontario representing 37% of the Canadian market for LMWHs, the listing of Redesca on the Ontario public formulary is a key milestone for the Redesca commercialization program", said Frederic Fasano, President and COO of Valeo.
  • "This is welcome news for millions of Canadians who rely on public insurance to access their prescription medications and for the Government of Ontario who will benefit from significant savings resulting from the listing of the first LMWH biosimilar.
  • We anticipate additional provincial coverage will follow", added Mr. Fasano.\nRedesca is a low molecular weight heparin biosimilar.
  • LMWHs are injectable anticoagulant drugs used primarily to treat and prevent deep vein thrombosis and pulmonary embolism.

Valeo Pharma Completes Negotiations with Pan-Canadian Pharmaceutical Alliance for Redesca® and Redesca HP®

Retrieved on: 
Tuesday, April 6, 2021
Heparins, Life sciences, Health sciences, Health care, Biotechnology, Pharmaceutical industry, Pan-Canadian Pharmaceutical Alliance, Low-molecular-weight heparin, Biosimilar, Medication, Leo Pharma

(CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a Canadian specialty pharmaceutical company, today announced that it has completed its negotiations and entered into a letter of intent ("LOI") with the pan-Canadian Pharmaceutical Alliance (pCPA) regarding Redesca and Redesca HP, its low molecular weight heparin ("LMWH") biosimilar, for the prevention and treatment of thromboembolic disorders.

Key Points: 
  • (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a Canadian specialty pharmaceutical company, today announced that it has completed its negotiations and entered into a letter of intent ("LOI") with the pan-Canadian Pharmaceutical Alliance (pCPA) regarding Redesca and Redesca HP, its low molecular weight heparin ("LMWH") biosimilar, for the prevention and treatment of thromboembolic disorders.
  • "The successful conclusion of negotiations with pCPA is a significant milestone delivered for the Redesca commercialization program.
  • Redesca has more than 8 years of proven in-market safety internationally and more than 150 million patient days treated in Europe alone.
  • Valeo Pharma is a Canadian pharmaceutical company dedicated to the commercialization of innovative prescription products in Canada with a focus on Respiratory Diseases, Neurodegenerative Diseases, Oncology and Hospital Specialty Products.

Industry Players in Heparin Market Working Concertedly to Commercialize Affordable and Effacious Products, Market to Garner CAGR of 6.8% during 2019 - 2027

Retrieved on: 
Wednesday, March 10, 2021
Chemical compounds, Organic compounds, Chemistry, Anticoagulant, Coagulation system, Glycosaminoglycans, Heparins, Apixaban, Coagulation, Dabigatran, Direct Xa inhibitor

The heparin market has witnessed rapid strides from relentless efforts of healthcare companies to unveil affordable and safer anticoagulants in patient populations.

Key Points: 
  • The heparin market has witnessed rapid strides from relentless efforts of healthcare companies to unveil affordable and safer anticoagulants in patient populations.
  • Clocking a CAGR of 6.8% from 2019 to 2027, the market is projected to climb to a valuation of US$ 19.4 Bn by 2027-end.
  • The high mortality of various coagulation disorders is a key trend boosting the prospects in the heparin market.
  • Several other alternatives are being explored such as dabigatran, apixaban, and rivaroxaban, which might hamper the revenue prospects in the heparin market.

Industry Players in Heparin Market Working Concertedly to Commercialize Affordable and Effacious Products, Market to Garner CAGR of 6.8% during 2019 - 2027

Retrieved on: 
Wednesday, March 10, 2021
Chemical compounds, Organic compounds, Chemistry, Anticoagulant, Coagulation system, Glycosaminoglycans, Heparins, Apixaban, Coagulation, Dabigatran, Direct Xa inhibitor

The heparin market has witnessed rapid strides from relentless efforts of healthcare companies to unveil affordable and safer anticoagulants in patient populations.

Key Points: 
  • The heparin market has witnessed rapid strides from relentless efforts of healthcare companies to unveil affordable and safer anticoagulants in patient populations.
  • Clocking a CAGR of 6.8% from 2019 to 2027, the market is projected to climb to a valuation of US$ 19.4 Bn by 2027-end.
  • The high mortality of various coagulation disorders is a key trend boosting the prospects in the heparin market.
  • Several other alternatives are being explored such as dabigatran, apixaban, and rivaroxaban, which might hamper the revenue prospects in the heparin market.

Insights on the Global Heparin Market 2020-2024: COVID-19 Industry Analysis, Market Trends, Market Growth, Opportunities and Forecast 2024 - Technavio

Retrieved on: 
Wednesday, March 3, 2021
Cash flow, Valuation, Heparins, Forecast period, Compound annual growth rate, Subcutaneous, Academic disciplines

NEW YORK, March 3, 2021 /PRNewswire/ --The heparin market is expected to grow by USD 941.2 mn, progressing at a CAGR of almost 3% during the forecast period.

Key Points: 
  • NEW YORK, March 3, 2021 /PRNewswire/ --The heparin market is expected to grow by USD 941.2 mn, progressing at a CAGR of almost 3% during the forecast period.
  • Get Free Sample Report in MINUTES
    The increasing prevalence of chronic conditions is one of the major factors propelling market growth.
  • Based on the product, the subcutaneous injection segment is expected to witness lucrative growth during the forecast period.
  • By geography, Europe is going to have a lucrative growth during the forecast period.

Apotex Corp. Issues Voluntary Nationwide Recall of Enoxaparin Sodium Injection, USP Due to Mislabeling of Syringe Barrel Measurement Markings

Retrieved on: 
Tuesday, February 2, 2021
Marketing, Pharmaceutical companies, Companies, Heparins, Apotex, Enoxaparin sodium, FedEx, Notification, Unique selling proposition

The two (2) affected batches of Enoxaparin Sodium Injection, USP were distributed by Apotex nationwide in the USA to Wholesalers and Warehousing Chains.

Key Points: 
  • The two (2) affected batches of Enoxaparin Sodium Injection, USP were distributed by Apotex nationwide in the USA to Wholesalers and Warehousing Chains.
  • Apotex Corp. is currently notifying its affected direct account Wholesalers and Warehousing Chains, via mail (FedEx Standard Overnight) by mailing a recall notification letter and is arranging for return of all recalled product.
  • Patients who have received either of the two (2) impacted batches of Enoxaparin Sodium Injection, USP or have questions regarding this recall should contact their pharmacy.
  • Consumers with questions regarding this recall can contact Apotex Corp. by phone at 1-800-706-5575 (8:30am 5:00pm, EST Monday thru Friday) or email address [email protected] .

Veralox Therapeutics Announces FDA Orphan Drug Designation for VLX-1005

Retrieved on: 
Tuesday, January 26, 2021
Biotechnology, FDA, Health, Pharmaceutical, Clinical trials, Life sciences, Health sciences, Health, Heparins, Biotechnology law, Drug discovery, Orphan drug, Pharmaceuticals policy, Thrombocytopenia, VLX-1005, Veralox Therapeutics

Veralox Therapeutics, a biotechnology company developing first-in-class small molecule therapeutics that treat the underlying pathologies of diseases with significant unmet medical needs, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for VLX-1005 for the treatment of heparin induced thrombocytopenia (HIT).

Key Points: 
  • Veralox Therapeutics, a biotechnology company developing first-in-class small molecule therapeutics that treat the underlying pathologies of diseases with significant unmet medical needs, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for VLX-1005 for the treatment of heparin induced thrombocytopenia (HIT).
  • We are pleased the FDA has granted Orphan Drug Designation for VLX-1005 for prophylaxis of thrombosis in patients with heparin-induced thrombocytopenia, said Jeffrey W. Strovel, PhD, Chief Executive Officer of Veralox Therapeutics.
  • Orphan drug designation provides eligibility for certain development incentives, including tax credits for qualified clinical testing, prescription drug user fee exemptions and seven-year marketing exclusivity upon FDA approval.
  • VERALOX Therapeutics Inc. ( https://veralox.com/ ) is developing first-in-class therapeutics that target the underlying pathologies of diseases with unmet medical needs.